,,ii #aagth ,,congress #ast ,session ,s4 #adeg ,,in ,,the ,,senate ,,of ,,the ,,united ,,states ,april #bi1 #bjba,mr4 ,markey 7for himself1 ,ms4 ,warren1 ,mr4 ,whitehouse1 ,ms4 ,baldwin1 and ,mr4 ,booker7 introduced the following bill2 which was read twice and referred to the ,committee on ,health1 ,education1 ,labor1 and ,pensions ,a ,,bill ,to establish programs to address addiction and overdoses caused by illicit fentanyl and other opioids1 and for other purposes4 #a4 ,short title2 table of contents 7a7 ,short title ,this ,act may be cited as the ,support1 ,treatment1 and ,overdose ,prevention of ,fentanyl ,act of #bjba or the ,,stop ,fentanyl ,act of #bjba4 7b7 ,table of contents ,the table of contents for this ,act is as follows3 ,sec4 #a4 ,short title2 table of contents4,sec4 #b4 ,definitions4,sec4 #c4 ,findings4,,title ,i--,fentanyl ,research and ,education,sec4 #aja4 ,enhanced fentanyl surveillance4,sec4 #ajb4 ,collection of overdose data4,sec4 #ajc4 ,fentanyl detection4,sec4 #ajd4 ,,gao report on international mail and cargo screening4,sec4 #aje4 ,contingency management program4,,title ,,ii--,overdose ,prevention and ,substance ,use ,disorder ,treatment ,programs,sec4 #bja4 ,,nam report on overdose prevention centers4,sec4 #bjb4 ,naloxone4,sec4 #bjc4 ,good ,samaritan immunity4,sec4 #bjd4 ,medication-assisted treatment4,sec4 #bje4 ,telehealth for substance use disorder treatment4,sec4 #bjf4 ,grant program on harms of drug misuse4,sec4 #bjg4 ,opioid treatment education4,,title ,,iii--,public ,health ,data and ,training ,support for ,fentanyl ,detection,sec4 #cja4 ,public health support for law enforcement4,sec4 #cjb4 ,report on countries that produce synthetic drugs4,sec4 #cjc4 ,grants to improve public health surveillance in forensic laboratories4 #b4 ,definitions ,in this ,act1 except as otherwise provided3 7#a7 ,the term ,assistant ,secretary means the ,assistant ,secretary for ,mental ,health and ,substance ,use4 7#b7 ,the term ,secretary means the ,secretary of ,health and ,human ,services4 7#c7 ,the term fentanyl-related substance has the meaning given the term in section #acjh4aa7;h77#cj77;i7 of title #ba1 ,code of ,federal ,regulations 7or successor regulations74 #c4 ,findings ,congress finds the following3 7#a7 ,the opioid epidemic has led to a rise in overdose deaths across the ,nation4 7#b7 ,in #bjag1 the number of overdose deaths involving opioids1 including fentanyl1 was #f times higher than in #aiii4 7#c7 ,the age-adjusted rate of drug overdose deaths involving synthetic opioids other than methadone increased by #aj percent from #bjag to #bjah4 7#d7 ,the ,,covid-#ai pandemic has been associated with substance use4 ,according to the ,centers for ,disease ,control and ,prevention 7,,cdc71 #ac percent of surveyed adults had started or increased substance use to cope with stress or emotions related to ,,covid-#ai4 7#e7 ,federal agencies1 along with ,federal1 ,state1 and local lawmakers1 have worked together to respond to the rise in overdose deaths through increased funding and targeted policy initiatives4 7#f7 ,this includes the successful passage of the ,comprehensive ,addiction and ,recovery ,act of #bjaf 7,,cara71 the #bast ,century ,cures ,act1 and the ,substance ,use-,disorder ,prevention that ,promotes ,opioid ,recovery and ,treatment for ,patients and ,communities ,act 7,,support for ,patient and ,communities ,act74 7#g7 ,these efforts have helped prevent1 treat1 and combat the opioid epidemic1 but the rise in overdose deaths involving synthetic opioids like fentanyl means that not all communities are seeing a reduction in fatalities4 7#h7 ,drug overdose deaths in the ,united ,states involving fentanyl have risen from #bjaa through #bjaf1 growing from #a1fjj fentanyl overdose related deaths in #bjaa and #bjab to #ah1jjj deaths in #bjaf4 7#i7 ,this rise in fentanyl overdose related deaths has disproportionately impacted communities of color4 7#aj7 ,according to the ,centers for ,disease ,control and ,prevention 7,,cdc71 drug overdose death rates involving fentanyl for non-,hispanic ,african ,americans had the largest annual percentage increase from #bjaa to #bjaf at #adj4f percent per year1 followed by ,hispanic persons at #aah4c percent per year4 ,fentanyl-involved overdose rates for non-,hispanic ,white persons increased by #ajh4h percent from #bjac to #bjaf4 7#aa7 ,according to the ,,cdc1 rates of drug overdose deaths involving fentanyl increased exponentially from #bjaa through #bjaf for most regions of the ,united ,states4 7#ab7 ,fentanyl is increasingly being identified in nonopioid substances1 like methamphetamine and cocaine4 7#ac7 ,by #bjag1 over half of heroin and cocaine overdose death records involved synthetic opioids4 7#ad7 ,previous policies to counter the widespread use of illicit substances through tougher sentencing guidelines disproportionately impact communities of color4 7#ae7 ,there is a growing need for a comprehensive plan focused on monitoring1 researching1 treating1 and preventing fentanyl overdose deaths4 7#af7 ,taking a public health approach to reversing overdose death trends and promoting equity should emphasize increasing research and expanding access to treatment4 ,i ,fentanyl ,research and ,education #aja4 ,enhanced fentanyl surveillance 7a7 ,in general ,the ,director of the ,centers for ,disease ,control and ,prevention shall enhance the drug surveillance program of the ,centers by-- 7#a7 expanding such surveillance program to include all #ej ,states1 the territories of the ,united ,states1 and all ,tribes and ,tribal organizations2 7#b7 increasing and accelerating the collection of data on fentanyl1 fentanyl-related substances1 other synthetic opioids1 and new emerging drugs of abuse1 including related overdose data from medical examiners and drug treatment admissions and information regarding drug seizures2 and 7#c7 utilizing available and emerging information on fentanyl1 fentanyl-related substances1 other synthetic opioids1 and new emerging drugs of abuse1 including information from-- 7,a7 the ,national ,drug ,early ,warning ,system2 7,b7 ,state and local public health authorities2 7,c7 ,federal1 ,state1 and local public health laboratories2 and 7,d7 drug seizures by ,federal1 ,state1 and local law enforcement agencies1 including information from the ,national ,seizure ,system and the ,national ,forensic ,laboratory ,information ,system of the ,drug ,enforcement ,administration4 7b7 ,information sharing ,the ,director of the ,centers for ,disease ,control and ,prevention shall share the information collected through the drug surveillance program of the ,centers with entities including the ,office of ,national ,drug ,control ,policy1 ,state and local public health agencies1 and ,federal1 ,state1 and local law enforcement agencies4 7c7 ,law enforcement reporting ,each ,federal law enforcement agency shall report information on all drug seizures by that agency to the ,drug ,enforcement ,administration for inclusion in the ,national ,seizure ,system4 7d7 ,,gao report ,not later than #b years after the date of enactment of this ,act1 the ,comptroller ,general of the ,united ,states shall-- 7#a7 publish a report analyzing how ,federal agencies can improve their collection1 reporting1 sharing1 and analytic use of drug seizure data across ,federal agencies and with ,state and local governments2 and 7#b7 include in such report an analysis of how well available data on drug seizures can measure progress toward reducing drug trafficking into and within the country1 as outlined in strategies such as the ,national ,drug ,control ,strategy of the ,office of ,national ,drug ,control ,policy4 7e7 ,authorization of appropriations ,to carry out this section1 there is authorized to be appropriated #abe1jjj1jjj for each of fiscal years #bjbb through #bjbf4 #ajb4 ,collection of overdose data 7a7 ,in general ,not later than one year after the date of enactment of this ,act1 the ,secretary shall conduct a study on how to most efficiently track overdoses by type of drug1 including fentanyl4 7b7 ,grant program 7#a7 ,in general ,upon completion of the study under subsection 7a71 and taking into consideration the results of such study1 the ,secretary shall award grants to ,states to facilitate the collection of data with respect to fentanyl-involved overdoses4 7#b7 ,requirement ,as a condition on receipt of a grant under this subsection1 an applicant shall agree to share the data collected pursuant to the grant with the ,centers for ,disease ,control and ,prevention4 7#c7 ,preference ,in awarding grants under this subsection1 the ,secretary shall give preference to applicants whose grant proposals demonstrate the greatest need for collecting timely and accurate data on overdoses4 #ajc4 ,fentanyl detection 7a7 ,testing of contaminants 7#a7 ,in general ,the ,secretary1 acting through the ,assistant ,secretary and in coordination with the ,director of the ,centers for ,disease ,control and ,prevention1 shall establish a pilot program through which #e entities1 in #e ,states representing diverse regions1 use chemical screening devices to identify contaminants1 including fentanyl and fentanyl-related substances1 in illicit street drugs4 7#b7 ,evaluation ,not later than the end of fiscal year #bjbe1 the ,secretary shall-- 7,a7 complete an evaluation of the most effective ways of expanding the pilot program under this subsection to decrease rates of overdose2 and 7,b7 submit a report to the appropriate congressional committees on the results of such evaluation4 7#c7 ,definition ,in this subsection1 the term chemical screening device means an infrared spectrophotometer1 mass spectrometer1 nuclear magnetic resonance spectrometer1 ,raman spectrophotometer1 ion mobility spectrometer1 or any other device or other technology that is able to determine the presence of1 or identify1 one or more contaminants in illegal street drugs4 7#d7 ,authorization of appropriations ,to carry out this subsection1 there is authorized to be appropriated #e1jjj1jjj for each of fiscal years #bjbb through #bjbf4 7b7 ,research into technologies 7#a7 ,in general ,the ,secretary shall conduct or support research for the development or improvement of portable and affordable technologies related to testing drugs for fentanyl and fentanyl-related substances1 including chemical screening device methods4 7#b7 ,authorization of appropriations ,to carry out this subsection1 there is authorized to be appropriated #be1jjj1jjj for each of fiscal years #bjbb through #bjbf4 #ajd4 ,,gao report on international mail and cargo screening ,not later than #a year after the date of enactment of this ,act1 the ,comptroller ,general of the ,united ,states shall submit to ,congress a report reviewing the impact of illicit fentanyl and fentanyl-related substances imported through international mail and cargo1 including discussion of the following3 7#a7 ,the volume of fentanyl and fentanyl-related substances being imported into the ,united ,states by means of international mail and cargo4 7#b7 ,the potential impact of increased screening for illicit fentanyl and fentanyl-related substances on-- 7,a7 deterring drug trafficking in the ,united ,states2 7,b7 interdicting fentanyl and fentanyl-related substances that were manufactured outside of the ,united ,states and intended1 or attempted1 to be imported into the ,united ,states2 7,c7 the number of ,federal criminal prosecutions based on the manufacture1 distribution1 or possession of fentanyl or fentanyl-related substances1 disaggregated by demographic data1 including sex1 race1 and ethnicity1 of the offender2 7,d7 the charges brought in prosecutions described in subparagraph 7,c72 7,e7 the impacts of prosecutions described in subparagraph 7,c7 on reducing demand for1 and availability to users of1 fentanyl and fentanyl-related substances2 and 7,f7 the development of new fentanyl-related substances4 7#c7 ,the need for non-invasive technology in screening for fentanyl and fentanyl-related substances1 taking into account the findings under paragraphs 7#a7 and 7#b74 #aje4 ,contingency management program 7a7 ,in general ,the ,secretary shall-- 7#a7 develop and implement a program of using contingency management principles to discourage the use of illicit drugs2 and 7#b7 as part of such program use incentive-based interventions-- 7,a7 to increase substance misuse treatment retention2 and 7,b7 to promote adherence to treatment goals1 including negative urinalysis4 7b7 ,authorization of appropriations ,to carry out this section1 there is authorized to be appropriated #be1jjj1jjj for each of fiscal years #bjbb through #bjbf4 ,,ii ,overdose ,prevention and ,substance ,use ,disorder ,treatment ,programs #bja4 ,,nam report on overdose prevention centers ,not later than one year after the date of enactment of this ,act1 the ,comptroller ,general of the ,united ,states shall enter into an arrangement with the ,national ,academy of ,medicine 7or1 if the ,academy declines1 another appropriate entity7 to-- 7#a7 submit to ,congress a report on overdose prevention centers2 and 7#b7 include in such report-- 7,a7 a review of the effectiveness of legally authorized overdose prevention centers in the ,united ,states and abroad on lowering overdose deaths2 and 7,b7 an assessment of the effectiveness of overdose prevention centers on improving access to medication-assisted treatment and recovery services4 #bjb4 ,naloxone 7a7 ,naloxone pricing transparency 7#a7 ,reporting requirement ,not later than the date that is one year after the date of enactment of this ,act1 and annually thereafter1 to better understand how research and development costs1 manufacturing and marketing costs1 acquisitions1 ,federal investments1 revenues and sales1 and other factors influence drug prices1 each manufacturer of naloxone or any other drug approved by the ,food and ,drug ,administration for opioid overdose reversal shall report to the ,secretary-- 7,a7 with respect to naloxone 7or such other drug7-- 7i7 total expenditures of the manufacturer on-- 7,i7 materials and manufacturing for such drug2 7,,ii7 acquiring patents and licensing2 and 7,,iii7 costs to purchase or acquire the drug from another company1 if applicable2 7ii7 the percentage of total expenditures of the manufacturer on research and development for such drug that was derived from ,federal funds2 7iii7 the total expenditures of the manufacturer on research and development for such drug2 7iv7 the total revenue and net profit generated from the applicable drug for each calendar year since drug approval2 7v7 the total expenditures of the manufacturer that are associated with marketing and advertising for such drug2 7vi7 the wholesale acquisition cost for such drug2 7vii7 the average out-of-pocket cost of such drug to the consumer2 and 7viii7 patient utilization rates for such drug2 and 7,b7 additional information specific to the manufacturer as the ,secretary may require1 to include at a minimum-- 7i7 the total revenue and net profit of the manufacturer for the reporting period2 7ii7 metrics used to determine executive compensation2 and 7iii7 any additional information related to drug pricing decisions of the manufacturer1 such as total expenditures on-- 7,i7 drug research and development2 or 7,,ii7 clinical trials on drugs that failed to receive approval by the ,food and ,drug ,administration4 7#b7 ,reporting period ,the reporting period for the reports under paragraph 7#a7 shall be as follows3 7,a7 ,for the initial report under paragraph 7#a71 the #aj-year period preceding the report4 7,b7 ,for subsequent reports1 the #ab-month period preceding the respective reports4 7#c7 ,publicly available 7,a7 ,in general ,subject to subparagraph 7,b71 not later than #cj days after receiving the information under paragraph 7#a71 the ,secretary shall post on the internet website of the ,centers for ,medicare ,medicaid ,services the information reported under paragraph 7#a7 in written format and using language that is easily understandable by beneficiaries under titles ,,xviii and ,,xix of the ,social ,security ,act 7#db ,u4,s4,c4 #acie et seq42 #acif et seq474 7,b7 ,exclusion of proprietary information ,the ,secretary shall exclude proprietary information1 such as trade secrets and intellectual property1 submitted by the manufacturer under paragraph 7#a7 from the posting described in subparagraph 7,a74 7b7 ,study on classification of naloxone as a prescription drug ,the ,commissioner of ,food and ,drugs shall-- 7#a7 not later one year after the date of enactment of this ,act1 determine whether naloxone should remain subject to the requirements of section #ejc7;b77#a7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cec7;b77#a77 or be reclassified as an over-the-counter drug2 and 7#b7 take such actions as may be appropriate1 consistent with such determination4 #bjc4 ,good ,samaritan immunity 7a7 ,limitation on civil liability for individuals who administer opioid overdose reversal drugs 7#a7 ,in general ,notwithstanding any other provision of law1 except as provided in paragraph 7#b71 no individual shall be liable in any ,federal or ,state proceeding for harm caused by the emergency administration of an opioid overdose reversal drug to an individual who has or reasonably appears to have suffered an overdose from heroin or another opioid1 if-- 7,a7 the individual who administers the opioid overdose reversal drug obtained the drug from-- 7i7 a health care professional as part of an opioid overdose prevention program2 or 7ii7 any source as permitted under applicable ,state law2 or 7,b7 the individual administers the opioid overdose reversal drug in good faith4 7#b7 ,exception ,paragraph 7#a7 shall not apply to an individual if the harm was caused by the gross negligence or reckless misconduct of the individual who administers the drug4 7#c7 ,definitions ,in this subsection3 7,a7 ,the term health care professional means a person licensed by a ,state to prescribe prescription drugs4 7,b7 ,the term opioid overdose reversal drug means a drug approved under section #eje of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cee7 that is indicated for the partial or complete reversal of the pharmacological effects of an opioid overdose in the human body4 7,c7 ,the term opioid overdose prevention program means a program operated by a local health department1 harm reduction or other community-based organization1 substance abuse treatment organization1 law enforcement agency1 fire department1 other first responder department1 or voluntary association1 or a program funded by a ,federal1 ,state1 or local government1 that works to prevent opioid overdoses by in part providing opioid overdose reversal drugs and education-- 7i7 to individuals at risk of experiencing an opioid overdose2 or 7ii7 to an individual in a position to assist another individual at risk of experiencing an opioid overdose4 7b7 ,immunity from liability 7#a7 ,in general ,an individual who1 in good faith and in a timely manner-- 7,a7 seeks medical assistance for another individual who is experiencing a drug overdose shall not be cited1 arrested1 prosecuted1 criminally liable1 or subject to any sanction for a violation of a condition of supervised release under section #djd of the ,controlled ,substances ,act 7#ba ,u4,s4,c4 #hdd7 for the possession or use of a controlled substance1 or under any other provision of ,federal law regulating the misuse of prescription drugs1 as a result of seeking such medical assistance2 or 7,b7 seeks medical assistance for himself or herself for a drug overdose1 or is the subject of a request for medical assistance described in subparagraph 7,a71 shall not be cited1 arrested1 prosecuted1 criminally liable1 or subject to any sanction for a violation of a condition of supervised release1 under section #djd of the ,controlled ,substances ,act 7#ba ,u4,s4,c4 #hdd7 for the possession or use of a controlled substance1 or under any other provision of ,federal law regulating the misuse of prescription drugs1 as a result of seeking such medical assistance4 7#b7 ,preemption ,this subsection preempts the laws of a ,state or any political subdivision of a ,state to the extent that such laws are inconsistent with this section1 unless such laws provide greater protection from liability4 7#c7 ,definitions ,in this section3 7,a7 ,the term controlled substance has the meaning given the term in section #ajb of the ,controlled ,substances ,act 7#ba ,u4,s4,c4 #hjb74 7,b7 ,the term drug overdose means an acute condition resulting from or believed to be resulting from the use of a controlled substance1 which an individual1 who is not a health care professional1 would reasonably believe requires medical assistance4 7,c7 ,the term prescription drug means a drug subject to section #ejc7;b77#a7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cec7;b77#a774 7,d7 ,the terms seeks medical assistance and seeking such medical assistance include-- 7i7 reporting a drug or alcohol overdose or other medical emergency to a law enforcement authority1 the #i-a-a system1 a poison control center1 or a medical provider2 7ii7 assisting another individual who is making a report described in clause 7i72 or 7iii7 providing care to someone who is experiencing a drug or alcohol overdose or other medical emergency while awaiting the arrival of medical assistance4 7c7 ,seeking assistance as a mitigating factor ,section #ceec of title #ah1 ,united ,states ,code1 is amended-- 7#a7 by redesignating subsection 7g7 as subsection 7h72 and 7#b7 by inserting after subsection 7f7 the following3 7g7 ,seeking medical assistance 7#a7 ,in general ,notwithstanding any other provision of law1 in imposing a sentence pursuant to guidelines promulgated by the ,united ,states ,sentencing ,commission under section #iid of title #bh against a defendant convicted of an offense as a result of seeking medical assistance for another individual who is experiencing a drug overdose1 or for himself or herself for a drug overdose1 other than an offense described in section #bjc7;b77#a77;,a7 of the ,,stop ,fentanyl ,act of #bjba1 the court shall consider the act of seeking medical assistance as a mitigating factor4 7#b7 ,definitions ,in this subsection1 the terms drug overdose and seeking medical assistance have the meanings given to such terms in section #bjc7;b7 of the ,,stop ,fentanyl ,act of #bjba4 4 #bjd4 ,medication-assisted treatment 7a7 ,opioid treatment program regulations 7#a7 ,definition ,in this subsection1 the term opioid treatment program means a program or practitioner engaged in opioid treatment of individuals with an opioid agonist treatment medication registered under section #cjc7;g77#a7 of the ,controlled ,substances ,act 7#ba ,u4,s4,c4 #hbc7;g77#a774 7#b7 ,elimination of patient eligibility requirement ,the ,secretary shall amend section #h4ab7;e77#a7 of title #db1 ,code of ,federal ,regulations 7and such other regulations in part #h of such title #db as may be necessary7 to eliminate the requirement that the person became addicted at least #a year before admission for maintenance treatment under an opioid treatment program4 7#c7 ,survey 7,a7 ,in general ,not later than one year after the date of enactment of this ,act1 the ,assistant ,secretary shall-- 7i7 complete a survey of the use in opioid treatment programs of take-home prescription medications2 and 7ii7 submit a report to ,congress on the findings of the survey4 7,b7 ,required assessment ,the survey under paragraph 7#a7 shall assess-- 7i7 the frequency of use of take-home medication1 as allowed under section #h4ab7;i7 of title #db1 ,code of ,federal ,regulations2 7ii7 the extent to which the limitations on doses for take-home use listed in section #h4ab7;i77#c77;i71 7ii71 7iii71 and 7iv7 of such title #db unduly burden treatment of individuals with opioid use disorder2 and 7iii7 whether and how individuals receiving medications for take-home use receive all services listed in section #h4ab7;f7 of such title #db4 7b7 ,treatment in rural and underserved populations ,not later than #a year after the date of enactment of this ,act1 the ,assistant ,secretary shall complete a study and submit a report to ,congress on ways in which the ,substance ,abuse and ,mental ,health ,services ,administration can provide and support health services1 including treatment for substance use disorders1 to individuals in rural 7including agricultural7 and medically underserved communities 7as defined in section #gii;,b of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #biep771 taking into account the following3 7#a7 ,stigma4 7#b7 ,using data4 7#c7 ,telemedicine4 7#d7 ,managing fiscal resources in a community impacted by addiction4 7#e7 ,workforce development4 7#f7 ,broadband4 7#g7 ,overcoming economic challenges4 7#h7 ,prevention4 7#i7 ,transportation4 7#aj7 ,nutritional services4 7#aa7 ,medication-assisted treatment4 7#ab7 ,educating law enforcement personnel about addiction4 7#ac7 ,drug courts4 7#ad7 ,educating the faith community about addiction4 7#ae7 ,recovery support4 7#af7 ,housing4 7#ag7 ,harm reduction services4 7c7 ,prisons and medication-,assisted treatment 7#a7 ,in general ,the ,director of the ,bureau of ,prisons shall establish a program to offer-- 7,a7 medication-assisted treatment for opioid use disorder to individuals in the custody of the ,bureau of ,prisons and include in such treatment all drugs that are approved by the ,food and ,drug ,administration to treat opioid use disorder2 and 7,b7 withdrawal management services to individuals in the custody of the ,bureau of ,prisons to provide a comprehensive treatment approach to substance use disorders4 7#b7 ,authorization of appropriations ,to carry out this subsection1 there is authorized to be appropriated to the ,director of the ,bureau of ,prisons #aej1jjj1jjj for each of fiscal years #bjbb through #bjbf4 7d7 ,residential substance abuse treatment for ,state prisoners ,section #aijd7;d7 of title ,i of the ,omnibus ,crime ,control and ,safe ,streets ,act of #aifh 7#cd ,u4,s4,c4 #ajdbd7;d77 is amended-- 7#a7 by striking means and inserting the following3 7#a7 means 2 and 7#b7 by striking the period at the end and inserting 2 and2 and 7#c7 by adding at the end the following3 7#b7 includes any such course of comprehensive individual and group substance abuse treatment services using medication-assisted treatment for opioid use disorder 7including the use of any drug approved or licensed by the ,food and ,drug ,administration for such treatment74 4 #bje4 ,telehealth for substance use disorder treatment ,section #cji7;e77#b7 of the ,controlled ,substances ,act 7#ba ,u4,s4,c4 #hbi7;e77#b77 is amended-- 7#a7 in subparagraph 7,a77i7-- 7,a7 by striking at least #a in-person medical evaluation and inserting the following3 at least-- 7,i7 #a in-person medical evaluation 2 and 7,b7 by adding at the end the following3 7,,ii7 for purposes of prescribing a controlled substance in schedule ,,iii or ,,iv1 #a telehealth evaluation2 or 2 and 7#b7 by adding at the end the following3 7,d7 7i7 ,the term telehealth evaluation means a medical evaluation that is conducted in accordance with applicable ,federal and ,state laws by a practitioner 7other than a pharmacist7 who is at a location remote from the patient and is communicating with the patient using a telecommunications system referred to in section #ahcd7m7 of the ,social ,security ,act 7#db ,u4,s4,c4 #aciem7m77 that includes1 at a minimum1 audio and video equipment permitting two-way1 real-time interactive communication between the patient and distant site practitioner4 7ii7 ,nothing in clause 7i7 shall be construed to imply that #a telehealth evaluation demonstrates that a prescription has been issued for a legitimate medical purpose within the usual course of professional practice4 7iii7 ,a practitioner who prescribes the drugs or combination of drugs that are covered under section #cjc7;g77#b77;,c7 using the authority under subparagraph 7,a77i77,,ii7 of this paragraph shall adhere to nationally recognized evidence-based guidelines for the treatment of patients with opioid use disorders and a diversion control plan1 as those terms are defined in section #h4b of title #db1 ,code of ,federal ,regulations1 as in effect on the date of enactment of this subparagraph4 4 #bjf4 ,grant program on harms of drug misuse 7a7 ,in general ,the ,assistant ,secretary1 in consultation with the ,director of the ,centers for ,disease ,control and ,prevention1 shall award grants to ,states1 political subdivisions of ,states1 ,tribes1 ,tribal organizations1 and community-based entities to support the delivery of overdose prevention1 syringe services programs1 and other harm reduction services that address the harms of drug misuse1 including by-- 7#a7 preventing and controlling the spread of infectious diseases1 such as ,,hiv_/,,aids and viral hepatitis1 and the consequences of such diseases for individuals with substance use disorder2 7#b7 distributing opioid antagonists1 such as naloxone1 to individuals at risk of overdose2 7#c7 connecting individuals at risk for1 or with1 a substance use disorder to overdose education1 counseling1 and health education2 and 7#d7 encouraging such individuals to take steps to reduce the negative personal and public health impacts of substance use or misuse4 7b7 ,considerations ,in awarding grants under this section1 the ,assistant ,secretary shall prioritize grants to applicants that are-- 7#a7 culturally specific organizations1 ,tribal behavioral health and substance use disorder providers1 or organizations that are intentional about serving populations where ,,covid-#ai has had the most impact2 or 7#b7 proposing to serve areas with-- 7,a7 a higher proportion of the population who meet criteria for dependence on1 or abuse of1 illicit drugs2 7,b7 a higher drug overdose death rate2 7,c7 a greater telemedicine infrastructure need2 and 7,d7 a greater behavioral health and substance use disorder workforce need4 7c7 ,use of grant awards ,a recipient of a grant under this section may use such grant funds for the following purposes3 7#a7 ,adapt1 maintain1 and expand essential services provided by harm reduction service organizations to address the risks of ,,covid-#ai1 drug overdose1 and contraction of infectious disease4 7#b7 ,maintain or hire staff4 7#c7 ,support program operational costs1 including staff1 rent1 and vehicle purchase or maintenance4 7#d7 ,program supplies4 7#e7 ,support and case management services4 7d7 ,authorization of appropriations ,to carry out this section1 there is authorized to be appropriated #ej1jjj1jjj for fiscal year #bjbb1 to remain available until expended4 #bjg4 ,opioid treatment education 7a7 ,in general ,the ,secretary shall award grants to ,states and local governmental entities to provide education to stakeholders1 including health care providers1 criminal justice professionals1 and substance use disorder treatment personnel1 on the current state of research on treatment for opioid dependence1 including-- 7#a7 the use of opioid agonists or partial agonists2 and 7#b7 the potential benefits of the use of opioid agonists or partial agonists for affected individuals4 7b7 ,authorization of appropriations ,to carry out this section1 there is authorized to be appropriated #ajj1jjj1jjj for each of fiscal years #bjbb through #bjbf4 ,,iii ,public ,health ,data and ,training ,support for ,fentanyl ,detection #cja4 ,public health support for law enforcement 7a7 ,support for fentanyl detection and handling ,the ,secretary1 in consultation with the ,attorney ,general1 shall establish a program to provide to ,federal1 ,state1 and local law enforcement agencies public health training on how to detect and handle fentanyl4 7b7 ,evidence-,based ,the program under subsection 7a7 shall comply with evidence-based guidelines1 including the ,fentanyl ,safety ,recommendations for ,first ,responders 7or any successor guidelines7 of the ,office of ,national ,drug ,control ,policy4 7c7 ,authorization of appropriations ,to carry out this section1 there is authorized to be appropriated #e1jjj1jjj for each of fiscal years #bjbb through #bjbf4 #cjb4 ,report on countries that produce synthetic drugs ,not later than #a year after the date of enactment of this ,act1 the ,secretary of ,state shall submit to ,congress a report-- 7#a7 identifying the countries the ,secretary determines are the principal producers of synthetic drugs trafficked into the ,united ,states2 7#b7 assessing how and why those countries are producing such drugs2 and 7#c7 describing measures the ,secretary plans to take to reduce the flow of such drugs into the ,united ,states4 #cjc4 ,grants to improve public health surveillance in forensic laboratories ,title ,i of the ,omnibus ,crime ,control and ,safe ,streets ,act of #aifh 7#cd ,u4,s4,c4 #ajaja et seq47 is amended by adding at the end the following3 ,,pp ,confronting the ,use of ,heroin1 ,fentanyl1 and ,associated ,synthetic ,drugs #cjfa4 ,authority to make grants to address public safety through improved forensic laboratory data 7a7 ,purpose ,the purpose of this section is to assist ,states and units of local government in-- 7#a7 carrying out programs to improve surveillance of seized heroin1 fentanyl1 and associated synthetic drugs to enhance public health2 and 7#b7 improving the ability of ,state1 tribal1 and local government institutions to carry out such programs4 7b7 ,grant authorization ,the ,attorney ,general1 acting through the ,director of the ,bureau of ,justice ,assistance1 may make grants to ,states and units of local government to improve surveillance of seized heroin1 fentanyl1 and associated synthetic drugs to enhance public health4 7c7 ,grant projects ,to improve surveillance of seized heroin1 fentanyl1 and associated synthetic drugs ,grants made under subsection 7b7 shall be used for programs1 projects1 and other activities to-- 7#a7 reimburse ,state1 local1 or other forensic science laboratories to help address backlogs of untested samples of heroin1 fentanyl1 and associated synthetic drugs2 7#b7 reimburse ,state1 local1 or other forensic science laboratories for procuring equipment1 technology1 or other support systems if the applicant for the grant demonstrates to the satisfaction of the ,attorney ,general that expenditures for such purposes would result in improved efficiency of laboratory testing and help prevent future backlogs2 7#c7 reimburse ,state1 local1 or other forensic science laboratories for improved1 real-time data exchange with the ,centers for ,disease ,control and ,prevention on fentanyl1 fentanyl-related substances1 and other synthetic drugs present in the local communities2 and 7#d7 support ,state1 tribal1 and local health department services deployed to address the use of heroin1 fentanyl1 and associated synthetic drugs4 7d7 ,limitation ,not less than #fj percent of the amounts made available to carry out this section shall be awarded for the purposes under paragraph 7#a7 or 7#b7 of subsection 7c74 7e7 ,authorization of appropriations ,there are authorized to be appropriated to carry out this section #aj1jjj1jjj for each of fiscal years #bjbb and #bjbc4 7f7 ,allocation 7#a7 ,population allocation ,seventy-five percent of the amount made available to carry out this section in a fiscal year shall be allocated to each ,state that meets the requirements of section #bhjb so that each ,state shall receive an amount that bears the same ratio to the #ge percent of the total amount made available to carry out this section for that fiscal year as the population of the ,state bears to the population of all ,states4 7#b7 ,discretionary allocation ,twenty-five percent of the amount made available to carry out this section in a fiscal year shall be allocated pursuant to the discretion of the ,attorney ,general for competitive grants to ,states or units of local government with high rates of primary treatment admissions for heroin and other opioids1 for use by ,state or local law enforcement agencies4 7#c7 ,minimum requirement ,each ,state shall receive not less than #j4f percent of the amount made available to carry out this section in each fiscal year4 7#d7 ,certain territories 7,a7 ,in general ,for purposes of the allocation under this section1 ,american ,samoa and the ,commonwealth of the ,northern ,mariana ,islands shall be considered as #a ,state4 7,b7 ,allocation amongst certain territories ,for purposes of subparagraph 7,a71 #fg percent of the amount allocated shall be allocated to ,american ,samoa and #cc percent shall be allocated to the ,commonwealth of the ,northern ,mariana ,islands4 4